---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-24-000036"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T16:26:44.091182+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q1 net sales down 9.8% to $610.8M; Life Science segment falls 25.3% YoY

## Summary
- Net sales $610.8M, down 9.8% YoY (currency-neutral -9.6%); operating income $44.7M vs $61.9M.
- Life Science segment $241.7M (-25.3% YoY) due to biotech/biopharma weakness; Clinical Diagnostics $368.6M (+4.7%) grew.
- Net income $383.9M ($13.45 diluted) vs $69.0M ($2.32), largely from fair value changes of Sartorius AG equity holdings.
- CEO Norman Schwartz: Q1 in line with expectations; cautiously optimistic for gradual biopharma recovery in H2 2024.
- Effective tax rate 21.8% vs 18.7% a year ago, affected by equity securities treatment.

## SEC filing metadata
- accession: 0000012208-24-000036
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220824000036/0000012208-24-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220824000036/bio-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-24-000036
- JSON: https://secwatch.observer/filing/0000012208-24-000036.json
- Plain text: https://secwatch.observer/filing/0000012208-24-000036.txt

## Key facts
- Earnings Releases
  BIO-RAD LABORATORIES, INC. reported the first quarter ended March 31, 2024 results: revenue $610.8 million, net income $383.9 million, EPS $13.45 per share, on a diluted basis.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $610.8 million
  - Net income: $383.9 million
  - EPS: $13.45 per share, on a diluted basis
  - Result: reported results
  source text: Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023. On a currency-neutral basis, quarterly sales decreased 9.6 percent compared to the same period in 2023. Life Science segment net sales for the first quarter were $241.7 million, a decrease of 25.3 percent compared to the same period in 2023. On a currency-neutral basis, Life Science segment sales decreased by 25.2 percent compared to the same quarter in 2023. The currency-neutral year-over-year sales decrease was broad-based and was primarily driven by ongoing weakness in the biotech and biopharma end-markets and the economic environment in China. Clinical Diagnostics segment net sales for the first quarter were $368.6 million, an increase
  evidence_url: https://www.sec.gov/Archives/edgar/data/12208/000001220824000036/0000012208-24-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.